Moleculin Biotech
MBRX
17 hedge funds and large institutions have $2.91M invested in Moleculin Biotech in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 8 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
23% less funds holding
Funds holding: 22 → 17 (-5)
32% less capital invested
Capital invested by funds: $4.26M → $2.91M (-$1.35M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$194K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$57.9K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$39.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$137K |
| 2 |
Millennium Management
New York
|
-$88K |
| 3 |
Bank of New York Mellon
New York
|
-$65K |
| 4 |
Morgan Stanley
New York
|
-$32K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$10K | -5 | Closed |
|
|
CTB
27
Country Trust Bank
Bloomington,
Illinois
| – | -$2K | -1 | Closed |
|
28
Wells Fargo
San Francisco,
California
| – | -$1.7K | -1 | Closed |
|
29
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1K | – | – |
|
MBRX Hedge Fund Activity: Q1 2020 in Review
17 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2020, worth a combined $2.91M — down 32% from $4.26M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MBRX and 3 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $194K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $137K sold.
- 17 institutional investors held Moleculin Biotech (MBRX) as of Q1 2020, down from 22 in Q4 2019.
- Funds reported $2.91M of Moleculin Biotech stock for Q1 2020, down 32% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q1 2020 and 8 closed out, a net change of -5 holders.
- The largest Moleculin Biotech buyer in Q1 2020 was Renaissance Technologies, an estimated $194K added.
- The largest Moleculin Biotech seller in Q1 2020 was Susquehanna International Group, an estimated $137K sold.
Based on aggregated 13F filings for Q1 2020.